Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Matasar MJ"" wg kryterium: Autor


Tytuł:
Advances in the diagnosis and management of lymphoma
Autorzy:
Matasar MJ
Word ZH
Pokaż więcej
Temat:
Diseases of the blood and blood-forming organs
RC633-647.5
Źródło:
Blood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 29-55 (2012)
Opis pliku:
electronic resource
Relacje:
http://www.dovepress.com/advances-in-the-diagnosis-and-management-of-lymphoma-a9203; https://doaj.org/toc/1179-9889
Dostęp URL:
https://doaj.org/article/3bba9cece3794f308c6fb307322869b4  Link otwiera się w nowym oknie
Czasopismo naukowe
Tytuł:
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Autorzy:
Flowers CR; Winship Cancer Institute of Emory University, Atlanta, GA. .
Matasar MJ; Memorial Sloan Kettering Cancer Center, New York, NY.
Herrera AF; City of Hope Medical Centre, Duarte, CA.
Hertzberg M; Prince of Wales Hospital and University of NSW, Sydney.
Assouline S; Jewish General Hospital, Montreal, QC.
Demeter J; Semmelweiss University, Budapest, Hungary.
McMillan A; Center for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham.
Mehta A; University of Alabama at Birmingham, Birmingham.
Opat S; Clinical Haematology, Monash Health and Monash University, Clayton.
Trnňný M; Charles University General Hospital, Prague, Czech Republic.
Musick L; Genentech, Inc., South San Francisco, CA.
Hirata J; Genentech, Inc., South San Francisco, CA.
Yang A; Genentech, Inc., South San Francisco, CA.
Sehn LH; BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2023 Sep 28. Date of Electronic Publication: 2023 Sep 28.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Autorzy:
Epstein-Peterson ZD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Drill E; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center.
Aypar U; Department of Pathology, Memorial Sloan Kettering Cancer Center.
Batlevi CL; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Caron P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center.
Drullinsky P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Gerecitano J; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Hamlin PA; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Ho C; Department of Pathology, Memorial Sloan Kettering Cancer Center.
Jacob A; Adaptive Biotechnologies, Seattle, WA.
Joseph A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Laraque L; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Matasar MJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Moskowitz AJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Moskowitz CH; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Mullins C; Adaptive Biotechnologies, Seattle, WA.
Owens C; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Salles G; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Schöder H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Straus DJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Younes A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Zelenetz AD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.
Kumar A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center. .
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2023 Aug 31. Date of Electronic Publication: 2023 Aug 31.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
Autorzy:
Buege MJ; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10018, USA.; Department of Pharmacy Practice, University of Illinois-Chicago College of Pharmacy, 833 S Wood Street, Chicago, Illinois, 60605, USA.
Drill E; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10018, USA.
Horwitz SM; Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10018, USA.
LeVoir A; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10018, USA.
Pak T; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10018, USA.
Peterson TJ; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10018, USA.
Dao PH; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10018, USA.
Matasar MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10018, USA.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2023 Jul; Vol. 111 (1), pp. 96-102. Date of Electronic Publication: 2023 Apr 01.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Non-Hodgkin*/complications
Heart Failure*/chemically induced
Heart Failure*/epidemiology
Heart Failure*/complications
Ventricular Dysfunction, Left*/chemically induced
Ventricular Dysfunction, Left*/complications
Adult ; Humans ; Retrospective Studies ; Incidence ; Cardiotoxicity/epidemiology ; Cardiotoxicity/etiology ; Antibiotics, Antineoplastic/therapeutic use ; Anthracyclines/adverse effects
Czasopismo naukowe
Tytuł:
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
Autorzy:
Zheng S; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Gupta K; New York Medical College, Valhalla, NY 10595, USA.
Goyal P; College of Osteopathic Medicine, Touro University California, Vallejo, CA 94592, USA.
Nakajima R; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA.
Michaud L; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA.
Batlevi CL; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Hamlin PA; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Horwitz S; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Kumar A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Matasar MJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Moskowitz AJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Moskowitz CH; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.; Sylvester Cancer Center, University of Miami, Miami, FL 33136, USA.
Noy A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Palomba ML; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Straus DJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Von Keudell G; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Falchi L; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Yahalom J; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Zelenetz AD; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Younes A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; AstraZeneca, 1800 Concord Pike, Wilmington, DE 19803, USA.
Salles G; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Schöder H; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Joffe E; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Mar 14; Vol. 15 (6). Date of Electronic Publication: 2023 Mar 14.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
Autorzy:
Qualls D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Imber BS; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Okwali M; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Hamlin PA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kumar A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lahoud OB; Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Matasar MJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Owens C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
North VS; Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Irving Medical Center - New York-Presbyterian Hospital, New York, New York, USA.
Schöder H; Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Salles G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Yahalom J; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Falchi L; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2023 Feb; Vol. 200 (4), pp. 524-527. Date of Electronic Publication: 2022 Dec 09.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Rituximab/therapeutic use ; Combined Modality Therapy ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Raport
Tytuł:
Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors.
Autorzy:
Salz T; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zabor EC; Department of Quantitative Health Sciences & Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Brown PN; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Dalton SO; Danish Cancer Society Research Center, Copenhagen, Denmark.
Raghunathan NJ; Department of General Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matasar MJ; Lymphoma Survivorship Clinic, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Steingart R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hjalgrim H; Statens Serum Institute, Copenhagen, Denmark.
Specht L; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Vickers AJ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Oeffinger KC; Department of Medicine, Duke Cancer Institute, Durham, NC, USA.
Johansen C; CASTLE - Cancer Late Effect Research, Oncology Clinic, Center for Surgery and Cancer, Copenhagen, Denmark.
Pokaż więcej
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2022 Sep; Vol. 61 (9), pp. 1064-1068. Date of Electronic Publication: 2022 Oct 18.
Typ publikacji:
Journal Article
MeSH Terms:
Cardiovascular Diseases*/epidemiology
Cardiovascular Diseases*/etiology
Myocardial Infarction*/epidemiology
Myocardial Infarction*/etiology
Lymphoma*/epidemiology
Lymphoma*/radiotherapy
Lymphoma, Non-Hodgkin*/epidemiology
Lymphoma, Non-Hodgkin*/radiotherapy
Adult ; Humans ; Middle Aged ; Risk Factors ; Survivors ; Heart Disease Risk Factors
Czasopismo naukowe
Tytuł:
PI3K inhibitors in haematological malignancies.
Autorzy:
Matasar MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: .
Hiemeyer F; Clinical Statistics, Bayer AG, Berlin, Germany.
Childs BH; Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seragnoli,' Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperintale, Universita di Bologna, Bologna, Italy.
Pokaż więcej
Źródło:
The Lancet. Oncology [Lancet Oncol] 2022 Aug; Vol. 23 (8), pp. e365.
Typ publikacji:
Letter; Comment
MeSH Terms:
Hematologic Neoplasms*/drug therapy
Phosphatidylinositol 3-Kinases*
Humans ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use
Opinia redakcyjna
Tytuł:
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Autorzy:
Lin RJ; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Owens CN; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Drill E; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York.
Iannotta A; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York.
Oliveros M; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York.
Schick DL; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York.
Noy A; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Gerecitano JF; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Drullinsky PR; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Caron PC; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Kumar A; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Matasar MJ; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Moskowitz C; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Korc-Grodzicki B; Department of Medicine, Weill Cornell Medical College, New York, NY; Department of Medicine, Geriatrics Service, Memorial Sloan Kettering Cancer Center, New York.
Zelenetz AD; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Salles GA; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York.
Hamlin PA; Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York. .
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2022 May 01; Vol. 107 (5), pp. 1144-1152. Date of Electronic Publication: 2022 May 01.
Typ publikacji:
Journal Article
MeSH Terms:
Cytokines*
Lymphoma, Large B-Cell, Diffuse*/diagnosis
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/pathology
Activities of Daily Living ; Aged ; Aging ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin/adverse effects ; Humans ; Middle Aged ; Pilot Projects ; Prednisone/adverse effects ; Prospective Studies ; Rituximab ; Treatment Outcome ; Vincristine/adverse effects
Czasopismo naukowe
Tytuł:
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
Autorzy:
Pak TK; Department of Pharmacy, New York, NY, USA.
Dixon BN; Department of Pharmacy, New York, NY, USA.
Buege MJ; Department of Pharmacy, New York, NY, USA.
Dao PH; Department of Pharmacy, New York, NY, USA.
Leary MH; Nursing, New York, NY, USA.
Jarrett JC; Nursing, New York, NY, USA.
Duggan TA; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.
Caron P; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Falchi L; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Hamlin P; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Hamilton A; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.
Matasar MJ; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Moskowitz A; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Noy A; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Owens CN; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.
Von Keudell G; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Younes A; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.
Zelenetz AD; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Kumar A; Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY, USA.; Department of Medicine Weill Cornell Medical College, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Apr; Vol. 63 (4), pp. 876-884. Date of Electronic Publication: 2021 Nov 16.
Typ publikacji:
Journal Article
MeSH Terms:
Cytarabine*
Lymphoma*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone ; Humans ; Outpatients ; Oxaliplatin ; Rituximab
Czasopismo naukowe
Tytuł:
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
Autorzy:
Sha F; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Okwali M; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alperovich A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Caron PC; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Falchi L; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hamilton A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hamlin PA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Horwitz SM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joffe E; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Khan N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kumar A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matasar MJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Moskowitz AJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Owens C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Palomba LM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rodriguez-Rivera I; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Currently employed at NEXT Oncology / Texas Oncology, San Antonio, TX, USA.
Straus D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
von Keudell G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yahalom J; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dogan A; Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Schöder H; Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Seshan VE; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Salles G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Younes A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Currently employed at AstraZeneca, Wilmington, DE, USA.
Batlevi CL; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2022 Feb 10; Vol. 12 (2), pp. 29. Date of Electronic Publication: 2022 Feb 10.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Follicular*/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Progression-Free Survival ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment.
Autorzy:
Danilov AV; City of Hope National Medical Center, Duarte, CA, USA.
Magagnoli M; Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
Matasar MJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2022 Feb 03; Vol. 27 (1), pp. 57-66.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/genetics
Biology ; Humans ; Precision Medicine
Czasopismo naukowe
Tytuł:
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Autorzy:
Matasar MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: .
Dreyling M; Department of Medicine III, LMU Hospital, München, Germany.
Leppä S; University of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland.
Santoro A; IRCCS Humanitas Clinical and Research Center, Rozzano, Italy; Humanitas University, Pieve Emanuele, Italy.
Pedersen M; Department of Hematology, HS Rigshospitalet, København, Denmark.
Buvaylo V; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ.
Fletcher M; Pharmaceuticals Division, Bayer PLC, Reading, UK.
Childs BH; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università di Bologna, Bologna, Italy.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2021 Nov; Vol. 21 (11), pp. e886-e894. Date of Electronic Publication: 2021 Jul 02.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Immunotherapy/*methods
Lymphoma, B-Cell/*drug therapy
Pyrimidines/*therapeutic use
Quinazolines/*therapeutic use
Rituximab/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Double-Blind Method ; Feasibility Studies ; Female ; Humans ; Male ; Middle Aged ; Pyrimidines/pharmacology ; Quinazolines/pharmacology ; Rituximab/pharmacology
Czasopismo naukowe
Tytuł:
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Autorzy:
Mehta-Shah N; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Lunning MA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Moskowitz AJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Boruchov AM; Department of Medicine, St. Francis Medical Center, Hartford, Connecticut, USA.
Ruan J; Department of Medicine, Weill Cornell Medical Center, New York, New York, USA.
Lynch P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Hamlin PA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Leonard J; Department of Medicine, Weill Cornell Medical Center, New York, New York, USA.
Matasar MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Myskowski PL; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Marzouk E; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nair S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sholklapper T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Minnal V; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Palomba ML; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Vredenburgh J; Department of Medicine, St. Francis Medical Center, Hartford, Connecticut, USA.
Kumar A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Noy A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Straus DJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Zelenetz AD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Schoder H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Rademaker J; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Schaffer W; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Galasso N; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ganesan N; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Horwitz SM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2021 Oct 01; Vol. 96 (10), pp. 1211-1222. Date of Electronic Publication: 2021 Jul 29.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Depsipeptides/*therapeutic use
Lenalidomide/*therapeutic use
Lymphoma/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Oligopeptides/*therapeutic use
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Depsipeptides/administration & dosage ; Depsipeptides/adverse effects ; Female ; Humans ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Maximum Tolerated Dose ; Middle Aged ; Oligopeptides/administration & dosage ; Oligopeptides/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Autorzy:
Bobillo S; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
Joffe E; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sermer D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mondello P; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ghione P; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Caron PC; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hamilton A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hamlin PA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Horwitz SM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Kumar A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Matasar MJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Batlevi CL; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Moskowitz A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Owens CN; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Palomba ML; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Straus D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
von Keudell G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Seshan VE; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Younes A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2021 Jun 16; Vol. 11 (6), pp. 113. Date of Electronic Publication: 2021 Jun 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Central Nervous System Neoplasms*/prevention & control
Central Nervous System Neoplasms*/secondary
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Methotrexate/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Injections, Spinal ; Male ; Middle Aged ; Prednisone/administration & dosage ; Recurrence ; Retrospective Studies ; Risk Factors ; Rituximab/administration & dosage ; Vincristine/administration & dosage
Czasopismo naukowe
Tytuł:
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Autorzy:
Matasar MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: .
Capra M; Centro de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.
Özcan M; Ankara University School of Medicine, Ankara, Turkey.
Lv F; Fudan University Shanghai Cancer Center, Shanghai, China.
Li W; The First Hospital of Jilin University, Changchun, China.
Yañez E; Oncology-Hematology Unit, Department of Internal Medicine, School of Medicine, University of La Frontera, Temuco, Chile.
Sapunarova K; Medical University, Plovdiv, Bulgaria.
Lin T; Sun Yat-sen University Cancer Center, Guangzhou, China.
Jin J; The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, China.
Jurczak W; Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland.
Hamed A; Petz Aladár Megyei Oktató Kórház, Győr, Hungary.
Wang MC; Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Baker R; Hollywood Private Hospital, Nedlands, WA, Australia.
Bondarenko I; Chemotherapy Department, City Dnipropetrovsk Multi-field Clinical Hospital, 4 DSMA, Dnipro, Ukraine.
Zhang Q; Harbin Medical University Cancer Hospital, Harbin, China.
Feng J; Jiangsu Cancer Hospital, Nanjing, China.
Geissler K; Sigmund Freud University, Vienna, Austria.
Lazaroiu M; SC Policlinica de Diagnostic Rapid SA, Brasov, Romania.
Saydam G; Ege Üniversitesi Tıp Fakültesi, Izmir, Turkey.
Szomor Á; Pécsi Tudományegyetem Klinikai Központ, Pécs, Hungary.
Bouabdallah K; Hematology and Cellular Therapy Department, University Hospital of Bordeaux, Bordeaux, France.
Galiulin R; Department of Chemotherapy for Children and Adults, Clinical Oncological Dispensary of Omsk Region, Omsk, Russian Federation.
Uchida T; Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
Soler LM; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Cao A; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Hiemeyer F; Pharmaceuticals Division, Bayer, Berlin, Germany.
Mehra A; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Childs BH; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Shi Y; Department of Medical Oncology, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: .
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Pokaż więcej
Źródło:
The Lancet. Oncology [Lancet Oncol] 2021 May; Vol. 22 (5), pp. 678-689. Date of Electronic Publication: 2021 Apr 10.
Typ publikacji:
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Non-Hodgkin/*drug therapy
Phosphoinositide-3 Kinase Inhibitors/*administration & dosage
Pyrimidines/*administration & dosage
Quinazolines/*administration & dosage
Rituximab/*administration & dosage
Aged ; Double-Blind Method ; Female ; Humans ; Lymphoma, Non-Hodgkin/mortality ; Male ; Middle Aged ; Pyrimidines/adverse effects ; Quinazolines/adverse effects ; Recurrence ; Rituximab/adverse effects ; Rituximab/therapeutic use
Czasopismo naukowe
Tytuł:
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
Autorzy:
Batlevi CL; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .
Sha F; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alperovich A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ni A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Division of Biostatistics, College of Public Health, Ohio State University, Columbus, OH, USA.
Smith K; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; The Royal Marsden Hospital, London, UK.
Ying Z; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Peking University Cancer Hospital, Beijing, China.
Soumerai JD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Caron PC; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Falchi L; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hamilton A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hamlin PA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Horwitz SM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joffe E; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kumar A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matasar MJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Moskowitz AJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Moskowitz CH; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.
Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Owens C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Palomba LM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Straus D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
von Keudell G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Seshan VE; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Younes A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2020 Jul 17; Vol. 10 (7), pp. 74. Date of Electronic Publication: 2020 Jul 17.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Follicular/*epidemiology
Adult ; Aged ; Aged, 80 and over ; Combined Modality Therapy ; Disease Management ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; Public Health Surveillance ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Survival Analysis ; Survival Rate ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
Cancer worry and empathy moderate the effect of a survivorship-focused intervention on quality of life.
Autorzy:
Parker PA; Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.; Department of Psychiatry, Weill Cornell Medical College, New York, New York, USA.
Banerjee SC; Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.; Department of Psychiatry, Weill Cornell Medical College, New York, New York, USA.
Matasar MJ; Department of Medicine, Weill Cornell Medical College, New York, New York, USA.; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Bylund CL; Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.; STEM Translational Communication Center, University of Florida, Gainesville, Florida, USA.
Schofield E; Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Li Y; Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.; Department of Psychiatry, Weill Cornell Medical College, New York, New York, USA.
Jacobsen PB; Division of Cancer Control & Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
Astrow AB; Department of Medicine, New York Methodist Hospital, Hematology and Oncology, Weill Cornell Medical College, New York, New York, USA.
Leventhal H; Department of Psychology, Rutgers University, New Brunswick, New Jersey, USA.
Horwitz S; Department of Medicine, Weill Cornell Medical College, New York, New York, USA.; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Kissane D; Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.; Department of Psychiatry, Weill Cornell Medical College, New York, New York, USA.; University of Notre Dame Australia, School of Medicine, and the Cunningham Centre for Palliative Care Research, St Vincent's Hospital, Sydney, Australia.
Pokaż więcej
Źródło:
Psycho-oncology [Psychooncology] 2020 Jun; Vol. 29 (6), pp. 1012-1018. Date of Electronic Publication: 2020 Mar 11.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Physician-Patient Relations*
Survivorship*
Neoplasms/*psychology
Patient Education as Topic/*methods
Quality of Life/*psychology
Adult ; Anxiety/prevention & control ; Empathy ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/therapy ; Random Allocation ; Social Support
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies